Abstract
Abstract Allergic asthma is an airway inflammation in the present of high serum IgE and large numbers of eosinophils which mediated by an imbalanced type II helper T cell (Th2) immune response. Mesenchymal stem cell (MSC) is a multipotent progenitor which shows immunomodulatory ability and thought to be a potential immunotherapy. In this study, we evaluated whether allogenic MSC suppress immune cells from allergic asthma patients and whether Th2 microenvironment cytokine affect the immunomodulatory properties of MSCs. To this end, peripheral blood mononuclear cells (PBMCs) from allergic asthma patients were cocultured with MSC and proliferation and cytokine production of PBMCs were assayed. In addition, MSCs were treated with Th2 cytokine IL-4 and immunosuppressive properties of MSCs were examined. Our results showed that MSC suppressed proliferation and the expression of activation marker CD25 of both CD4+ and CD8+ T cells form allergic asthma patients. Otherwise, Th2 cytokine production was also reduced. However, IL-4 did not affect the immunosuppressive properties of MSCs. It seems that MSCs did not response to IL-4 since the immunosuppression related genes COX2, IDO, IL6 and IL8 did not increase. In conclusion, MSC is able to reduce Th2 response in allergic disease and Th2 environment might not affect their immunosuppressive function.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
